Glycopeptides to drive an anti-tumour immune response and improve outcomes in cancer immunotherapies - Texts

Home
Main Navigation
Content
Search
Help

Font Standard Bold
Login

Research unit

INNOSUISSE

Project number

62192.1 IP-LS

Project title

Glycopeptides to drive an anti-tumour immune response and improve outcomes in cancer immunotherapies (Innolink: 101.651 IP-LS)

Texts for this project

	German	French	Italian	English
Short description		-	-
Abstract		-	-	-

Inserted texts

Category	Text
Short description (German)	Glycopeptides to drive an anti-tumour immune response and improve outcomes in cancer immunotherapies (Innolink: 101.651 IP-LS)
Short description (English)	Glycopeptides to drive an anti-tumour immune response and improve outcomes in cancer immunotherapies
Abstract (German)	Most cancer patients do not respond to immunotherapies. Altered glycosylation of tumors is a signature of cancer development, making glycans an emerging target. The project studies glycopeptides as novel therapeutics that steer immune responses to control tumor growth and enhance treatment response.